Evaluation of SNA001, a Novel Recombinant Human Thyroid Stimulating Hormone Injection, in Patients With Differentiated Thyroid Carcinoma

Yushen Gu, Hongrong Xu, Yan‐Ling Yang, Yan Xiu, Pengcheng Hu, Min Liu, Xiangqing Wang, Jun Song, Yan Di, Jian Wang, Xiaoxia Zhang, Tao Xu, Xuening Li, Hongcheng ShiFrontiers in Endocrinology 2021 · DOI

Abstract

SNA001 is a novel recombinant human thyroid stimulating hormone (rhTSH) developed to facilitate monitoring and ablation of differentiated thyroid carcinoma (DTC) without the debilitating effects of clinical hypothyroidism. This Phase I, dose-ascending study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SNA001 in 24 DTC patients across three dose levels (0.45 mg, 0.9 mg, and 1.35 mg). The study utilized a two-period design comparing SNA001-stimulated testing with traditional thyroid hormone withdrawal (THW). Results demonstrated that SNA001 is safe, exhibits dose-dependent metabolism, and achieves 100% qualitative diagnostic concordance with THW in whole-body scans (WBS). SNA001 effectively stimulates iodine-131 uptake and thyroglobulin (Tg) release while maintaining patient quality of life.

Introduction

Patients with differentiated thyroid carcinoma (DTC) require lifelong monitoring to detect recurrence or metastasis. Effective diagnostic tools, such as radioactive iodine-131 whole-body scans (WBS) and serum thyroglobulin (Tg) measurements, require elevated thyroid-stimulating hormone (TSH) levels (typically >30 mU/L) to maximize sensitivity. Historically, this elevation was achieved through Thyroid Hormone Withdrawal (THW), which requires patients to stop replacement therapy for several weeks, leading to severe clinical hypothyroidism.

While recombinant human TSH (rhTSH) alternatives like Thyrogen™ exist globally, they have not been available in mainland China. SNA001 was developed as a novel rhTSH analog to provide the necessary TSH spike without the physiological burden of withdrawal. This paper evaluates the clinical performance of SNA001 in a Phase I trial.

Methods

The researchers conducted a single-center, open-label, dose-ascending Phase I clinical trial involving 24 DTC patients who had previously undergone thyroidectomy. The study followed a unique two-period design to compare the novel drug against the established gold standard.

Figure 1: Schematic representation of the two-period study design comparing SNA001 administration with traditional thyroid hormone withdrawal (THW).

In the SNA001 Period, patients received two intramuscular injections of SNA001 (0.45 mg, 0.9 mg, or 1.35 mg) 24 hours apart while continuing their thyroid hormone therapy. Diagnostic testing (WBS and Tg) was performed following the injections. After a washout period of at least two weeks, patients entered the THW Period, where they ceased hormone therapy for 3–6 weeks until TSH levels naturally rose above 30 mU/L, at which point the diagnostic tests were repeated for comparison.

Results

Pharmacokinetics and Pharmacodynamics

SNA001 demonstrated linear, dose-proportional pharmacokinetics. Mean peak serum concentrations (Cmax) for the 0.45, 0.9, and 1.35 mg groups were 18.5, 26.7, and 37.0 ng/ml, respectively.

Figure 2: Serum concentration-time curves of SNA001 following intramuscular injection at three dose levels (0.45 mg, 0.9 mg, and 1.35 mg).

Crucially, the 1.35 mg dose was most effective at maintaining TSH levels above the 30 mU/L clinical threshold for a sufficient diagnostic window (3–4 days). No patients developed anti-TSH antibodies, indicating low immunogenicity.

Diagnostic Concordance and Quality of Life

The primary clinical success was the 100% qualitative concordance in WBS results between the two periods. Every lesion or area of residual tissue identified during the THW period was also successfully identified during the SNA001 period. While absolute Tg levels were generally higher in the THW period (in 78% of subjects), SNA001 stimulated Tg levels above the 1 ng/ml diagnostic cutoff in 89% of patients, proving sufficient for clinical monitoring.

Quality of life assessments showed that SNA001 successfully avoided the symptoms associated with THW, such as fatigue, weight gain, and constipation. The safety profile was excellent, with only mild, transient gastrointestinal adverse events reported.

Discussion and Conclusion

This Phase I trial confirms that SNA001 is a safe and effective alternative to thyroid hormone withdrawal for DTC patients. By providing a predictable TSH spike, it allows for accurate diagnostic imaging and biochemical testing without the morbidity of hypothyroidism.

While the study was limited by its small sample size and single-center nature, the results are highly promising. A Phase III confirmatory trial is currently underway to further validate these findings. If approved, SNA001 will offer a significant advancement in the standard of care for thyroid cancer patients in China, prioritizing both diagnostic accuracy and patient well-being.

Summary updated

Abstract

SNA001 is a novel recombinant human thyroid stimulating hormone (rhTSH). rhTSH has long been approved in several countries to facilitate monitoring and ablation of thyroid carcinoma without hypothyroidism caused by thyroid hormone withdrawal (THW). To assess the safety, tolerance, pharmacokinetic and pharmacodynamic properties of SNA001, the two-period (SNA001 period and THW period), dose-ascending study in well-differentiated thyroid cancer (DTC) patients was designed. Three doses (0.45 mg, 0.9 mg, and 1.35 mg) of SNA001 were intramuscularly injected, twice in the SNA001 period to stimulate iodine-131 uptake and thyroglobulin (Tg) release. 24 h after the last dose of SNA001, iodine-131 (111-185 MBq) was administrated, followed by whole-body scan (WBS) 48 h later. THW period began just after SNA001 washout and lasted for about 3-6 weeks. When TSH level was above 30 mU/L, iodine-131 (111-185 MBq) was administrated, followed by a WBS and Tg detection 48 h later. Twenty-four DTC patients after thyroidectomy were enrolled; mean peak concentrations of SNA001 in 0.45, 0.9, and 1.35 mg groups were 18.5, 26.7, and 37.0 ng/ml (about 244.7, 354.2, and 489.6 mU/L) respectively, within 28-32 h after first dose of SNA001. SNA001 was metabolized in a dose-dependent manner. The results of WBS and Tg release in the SNA001 period were compared with those in the THW period. Compared to Tg level in baseline, the Tg levels in SNA001 and THW periods were increased, with 78% of subjects showing higher Tg levels in the THW period. 100% of the patients had concordant qualitative results of the scans within two periods in three groups. Symptoms of hypothyroidism were relieved in the SNA001 period compared with THW period, though there was no significant difference in most of the scale scores. There were no serious adverse events related to SNA001; the most common adverse events were gastrointestinal symptoms of mild and transient nature. Thus, SNA001 promises to be a safe and effective method to stimulate iodine-131 uptake and Tg secretion during monitoring and ablation for DTC without the disadvantages of incidental hypothyroidism.
BibTeX
@inproceedings{gu2021evaluation,
  author = {Yushen Gu and Hongrong Xu and Yan‐Ling Yang and Yan Xiu and Pengcheng Hu and Min Liu and Xiangqing Wang and Jun Song and Yan Di and Jian Wang and Xiaoxia Zhang and Tao Xu and Xuening Li and Hongcheng Shi},
  title = {{Evaluation of SNA001, a Novel Recombinant Human Thyroid Stimulating Hormone Injection, in Patients With Differentiated Thyroid Carcinoma}},
  booktitle = {Frontiers in Endocrinology},
  year = {2021},
  doi = {10.3389/fendo.2020.615883},
}
Figure